Sign in or create an account to add this stock to your watchlist.
About Apollo Endosurgery (NASDAQ:APEN)
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company sells its products primarily in the United States, Europe, Australia, Brazil, and Canada. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APEN
CUSIPN/A
Phone512-279-5100
Debt
Debt-to-Equity Ratio0.79
Current Ratio1.98
Quick Ratio1.38
Price-To-Earnings
Trailing P/E Ratio-3.35
Forward P/E Ratio-4.20
P/E GrowthN/A
Sales & Book Value
Annual Sales$64.31 million
Price / Sales1.83
Cash FlowN/A
Price / CashN/A
Book Value$2.39 per share
Price / Book2.82
Profitability
EPS (Most Recent Fiscal Year)($2.01)
Net Income$-27,290,000.00
Net Margins-41.50%
Return on Equity-61.61%
Return on Assets-26.55%
Miscellaneous
Employees213
Outstanding Shares17,510,000
Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions
What is Apollo Endosurgery's stock symbol?
Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."
How were Apollo Endosurgery's earnings last quarter?
Apollo Endosurgery (NASDAQ:APEN) released its quarterly earnings data on Thursday, May, 3rd. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.07. The biotechnology company earned $15.74 million during the quarter, compared to analyst estimates of $16 million. Apollo Endosurgery had a negative net margin of 41.50% and a negative return on equity of 61.61%. View Apollo Endosurgery's Earnings History.
What price target have analysts set for APEN?
4 Wall Street analysts have issued twelve-month price objectives for Apollo Endosurgery's shares. Their forecasts range from $8.00 to $12.00. On average, they expect Apollo Endosurgery's stock price to reach $10.25 in the next year. View Analyst Ratings for Apollo Endosurgery.
What are Wall Street analysts saying about Apollo Endosurgery stock?
Here are some recent quotes from research analysts about Apollo Endosurgery stock:
- 1. According to Zacks Investment Research, "Apollo Endosurgery, Inc. is engaged in designing and manufacturing of medical devices for weight loss solutions and gastrointestinal disorders. The Company's product segment includes ORBERA (R), LAP-BAND (R) and OverStitch(TM). The ORBERA is an Intragastric Balloon System which is a weight loss aid for adults suffering from obesity. The LAP-BAND System is developed for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables endoscopic surgery. It operates primarily in Asia Pacific, European Office, Latin and South America and Costa Rica. Apollo Endosurgery, Inc., formerly known as Lpath, Inc., is headquatered in Austin, Texas. " (5/2/2018)
- 2. Northland Securities analysts commented, "We note that the ASMBS Statement is not a guarantee of reimbursement for Orbera." (2/8/2018)
Who are some of Apollo Endosurgery's key competitors?
Some companies that are related to Apollo Endosurgery include Endologix (ELGX), Inovio Pharmaceuticals (INO), Accuray (ARAY), Antares Pharma (ATRS), Utah Medical Products (UTMD), GenMark Diagnostics (GNMK), RenovaCare (RCAR), Westaim (WEDXF), T2 Biosystems (TTOO), Cytosorbents (CTSO), Pulse Biosciences (PLSE), Orthopediatrics (KIDS), Nuvectra (NVTR), IRadimed (IRMD) and SeaSpine (SPNE).
Who are Apollo Endosurgery's key executives?
Apollo Endosurgery's management team includes the folowing people:
- Mr. Todd Newton, CEO & Director (Age 55)
- Mr. Charles Tribié, Exec. VP of Operations (Age 65)
- Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
- Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
- Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
Has Apollo Endosurgery been receiving favorable news coverage?
News coverage about APEN stock has been trending very positive on Friday, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Apollo Endosurgery earned a media sentiment score of 0.65 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.69 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Apollo Endosurgery's major shareholders?
Apollo Endosurgery's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (1.89%), NJ State Employees Deferred Compensation Plan (0.90%), University of Texas Texas AM Investment Managment Co. (0.68%) and Dimensional Fund Advisors LP (0.35%). Company insiders that own Apollo Endosurgery stock include A/S Novo, Bret Schwartzhoff, Holdings A/S Novo, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP, Todd Newton and William D Jr Mcclellan. View Institutional Ownership Trends for Apollo Endosurgery.
Which major investors are selling Apollo Endosurgery stock?
Which major investors are buying Apollo Endosurgery stock?
APEN stock was purchased by a variety of institutional investors in the last quarter, including NJ State Employees Deferred Compensation Plan, Dimensional Fund Advisors LP and Russell Investments Group Ltd.. Company insiders that have bought Apollo Endosurgery stock in the last two years include Bret Schwartzhoff, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP, Todd Newton and William D Jr Mcclellan. View Insider Buying and Selling for Apollo Endosurgery.
How do I buy shares of Apollo Endosurgery?
Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apollo Endosurgery's stock price today?
One share of APEN stock can currently be purchased for approximately $6.7279.
How big of a company is Apollo Endosurgery?
Apollo Endosurgery has a market capitalization of $118.36 million and generates $64.31 million in revenue each year. The biotechnology company earns $-27,290,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Apollo Endosurgery employs 213 workers across the globe.
How can I contact Apollo Endosurgery?
Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]
MarketBeat Community Rating for Apollo Endosurgery (APEN)
MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Apollo Endosurgery (NASDAQ:APEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Apollo Endosurgery in the last 12 months. Their average twelve-month price target is $10.25, suggesting that the stock has a possible upside of 52.35%. The high price target for APEN is $12.00 and the low price target for APEN is $8.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $10.25 | $10.25 | $11.00 | $11.00 |
| Price Target Upside: | 52.35% upside | 75.21% upside | 79.74% upside | 157.09% upside |
Apollo Endosurgery (NASDAQ:APEN) Consensus Price Target History
Apollo Endosurgery (NASDAQ:APEN) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Apollo Endosurgery (NASDAQ:APEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Apollo Endosurgery (NASDAQ APEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 52.80%
Institutional Ownership Percentage: 32.77%
Apollo Endosurgery (NASDAQ APEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/9/2018 | Matthew S Crawford | Director | Buy | 4,038 | $6.20 | $25,035.60 | 53,715 |  |
| 1/3/2018 | Stonepine Capital, L.P. | Major Shareholder | Buy | 22,845 | $5.71 | $130,444.95 | 2,560,314 | |
| 12/29/2017 | Stonepine Capital, L.P. | Major Shareholder | Buy | 5,163 | $5.56 | $28,706.28 | 2,560,314 | |
| 12/26/2017 | Stonepine Capital, L.P. | Major Shareholder | Buy | 5,287 | $5.00 | $26,435.00 | 2,555,151 | |
| 12/22/2017 | Stonepine Capital, L.P. | Major Shareholder | Buy | 185,157 | $4.85 | $898,011.45 | 2,410,141 | |
| 12/20/2017 | Stonepine Capital, L.P. | Major Shareholder | Buy | 45,434 | $4.50 | $204,453.00 | 2,410,141 | |
| 11/7/2017 | Bret Schwartzhoff | VP | Buy | 9,500 | $4.24 | $40,280.00 | 15,631 | |
| 7/26/2017 | Holdings A/S Novo | Major Shareholder | Sell | 50,130 | $6.90 | $345,897.00 | 1,334,772 | |
| 7/25/2017 | Richard J Meelia | Director | Buy | 45,454 | $5.50 | $249,997.00 | 5,098 | |
| 7/25/2017 | Sciences L P Ptv II | Major Shareholder | Buy | 1,090,909 | $5.50 | $5,999,999.50 | | |
| 7/25/2017 | Stefanie L Cavanaugh | CFO | Buy | 4,545 | $5.50 | $24,997.50 | 9,166 | |
| 7/25/2017 | Todd Newton | CEO | Buy | 136,363 | $5.50 | $749,996.50 | 167,129 | |
| 5/18/2017 | Todd Newton | CEO | Buy | 2,121 | $6.22 | $13,192.62 | 29,544 | |
| 5/17/2017 | William D Jr. Mcclellan | Director | Buy | 2,000 | $6.33 | $12,660.00 | | |
| 5/11/2017 | A/S Novo | Major Shareholder | Sell | 105,000 | $5.63 | $591,150.00 | 1,455,472 | |
| 12/12/2014 | Daniel H Petree | Director | Buy | 10,000 | $2.79 | $27,900.00 | | |
| 8/20/2014 | Gary J G Atkinson | CFO | Buy | 5,000 | $3.10 | $15,500.00 | | |
| 8/19/2014 | Scott R Pancoast | CEO | Buy | 10,000 | $3.00 | $30,000.00 | | |
| 8/18/2014 | Scott R Pancoast | CEO | Buy | 10,000 | $3.22 | $32,200.00 | | |
| 12/19/2012 | Charles Mathews | Director | Buy | 5,000 | $4.98 | $24,900.00 | | |
| 12/18/2012 | Scott R Pancoast | CEO | Buy | 5,000 | $4.95 | $24,750.00 | | |
(Data available from 1/1/2013 forward)
Apollo Endosurgery (NASDAQ APEN) News Headlines
| Source: |
|
Apollo Endosurgery (NASDAQ:APEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Apollo Endosurgery (NASDAQ:APEN) Income Statement, Balance Sheet and Cash Flow Statement
Apollo Endosurgery (NASDAQ APEN) Stock Chart for Friday, May, 25, 2018
Loading chart…
